Symbols / ADVB Stock $5.73 -11.44% Advanced Biomed Inc.

Healthcare • Diagnostics & Research • United States • NCM
ADVB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Dr. Yi Lu Ph.D.
Exch · Country NCM · United States
Market Cap 7.82M
Enterprise Value 4.31M
Income 4.05M
Sales —
FCF (ttm) -10.74M
Book/sh 8.76
Cash/sh 2.41
Employees 31
Insider 10d —
IPO Mar 06, 2025
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 1.63
Forward P/E —
PEG —
P/S —
P/B 0.65
P/C —
EV/EBITDA -1.45
EV/Sales —
Quick Ratio 2.15
Current Ratio 8.56
Debt/Eq 7.54
LT Debt/Eq —
EPS (ttm) 3.52
EPS next Y —
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) —
Earnings (prior) —
ROA -26.90%
ROE 80.18%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 1.36M
Shs Float 368.84K
Insider Own 55.05%
Instit Own 0.16%
Short Float 6.61%
Short Ratio 0.05
Short Interest 49.19K
52W High 48.80
vs 52W High -88.26%
52W Low 3.61
vs 52W Low 58.73%
Beta —
Impl. Vol. —
Rel Volume 0.08
Avg Volume 494.36K
Volume 42.02K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $6.47
Price $5.73
Change -11.44%
About

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$5.73
Latest analyst target
3. DCF / Fair value
$-141.61
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.73
Low
—
High
—
Mean
—
News
RSS: Latest ADVB news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
2.54
-17.25%
3.07
+29.35%
2.37
+29.26%
1.84
Research And Development
0.88
-36.36%
1.38
-14.59%
1.62
-6.63%
1.73
Selling General And Administration
1.26
-4.61%
1.32
+111.73%
0.62
+1304.93%
0.04
General And Administrative Expense
1.26
-4.61%
1.32
+111.73%
0.62
+1304.93%
0.04
Salaries And Wages
0.76
+2.42%
0.74
+138.76%
0.31
0.00
Other Gand A
0.50
-13.63%
0.58
+84.88%
0.31
+604.89%
0.04
Total Expenses
2.54
-17.25%
3.07
+29.35%
2.37
+29.26%
1.84
Operating Income
-2.54
+17.25%
-3.07
-29.35%
-2.37
-29.26%
-1.84
EBITDA
-2.14
+20.84%
-2.71
-20.57%
-2.24
-26.15%
-1.78
Normalized EBITDA
-1.85
+9.63%
-2.04
-226.37%
-0.63
+64.79%
-1.78
Reconciled Depreciation
0.40
+9.41%
0.37
+188.42%
0.13
+118.90%
0.06
EBIT
-2.54
+17.25%
-3.07
-29.35%
-2.37
-29.26%
-1.84
Total Unusual Items
-0.29
+55.47%
-0.66
+59.09%
-1.62
0.00
Total Unusual Items Excluding Goodwill
-0.29
+55.47%
-0.66
+59.09%
-1.62
0.00
Special Income Charges
0.00
+100.00%
-0.15
+90.72%
-1.62
0.00
Impairment Of Capital Assets
—
0.00
-100.00%
1.62
0.00
Net Income
-2.78
+25.46%
-3.73
+7.32%
-4.03
-119.24%
-1.84
Pretax Income
-2.78
+25.46%
-3.73
+7.32%
-4.03
-119.24%
-1.84
Net Non Operating Interest Income Expense
0.05
+149.95%
0.02
+8707.41%
0.00
+767.86%
0.00
Net Interest Income
0.05
+149.95%
0.02
+8707.41%
0.00
+767.86%
0.00
Interest Income Non Operating
0.05
+149.95%
0.02
+8707.41%
0.00
+767.86%
0.00
Interest Income
0.05
+149.95%
0.02
+8707.41%
0.00
+767.86%
0.00
Other Income Expense
-0.29
+56.92%
-0.68
+58.70%
-1.65
-672092.68%
-0.00
Other Non Operating Income Expenses
0.00
+102.30%
-0.02
+40.73%
-0.04
-14379.67%
-0.00
Gain On Sale Of Security
-0.29
+42.40%
-0.51
—
—
Gain On Sale Of Business
0.00
+100.00%
-0.15
—
—
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-2.78
+25.46%
-3.73
+7.32%
-4.03
-119.24%
-1.84
Net Income From Continuing Operation Net Minority Interest
-2.78
+25.46%
-3.73
+7.32%
-4.03
-119.24%
-1.84
Net Income From Continuing And Discontinued Operation
-2.78
+25.46%
-3.73
+7.32%
-4.03
-119.24%
-1.84
Net Income Continuous Operations
-2.78
+25.46%
-3.73
+7.32%
-4.03
-119.24%
-1.84
Normalized Income
-2.49
+19.00%
-3.07
-27.44%
-2.41
-31.17%
-1.84
Net Income Common Stockholders
-2.78
+25.46%
-3.73
+7.32%
-4.03
-119.24%
-1.84
Diluted EPS
-2.57
+25.46%
-3.45
-435.33%
-0.64
—
Basic EPS
-2.57
+25.46%
-3.45
-435.33%
-0.64
—
Basic Average Shares
1.08
-82.69%
6.25
+0.00%
6.25
—
Diluted Average Shares
1.08
-82.69%
6.25
+0.00%
6.25
—
Diluted NI Availto Com Stockholders
-2.78
+25.46%
-3.73
+7.32%
-4.03
-119.24%
-1.84
Depreciation Amortization Depletion Income Statement
0.40
+9.41%
0.37
+180.80%
0.13
+124.83%
0.06
Depreciation And Amortization In Income Statement
0.40
+9.41%
0.37
+180.80%
0.13
+124.83%
0.06
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total Assets
—
4.46
-3.04%
4.60
-31.48%
6.71
Current Assets
—
3.05
+9.52%
2.79
-44.34%
5.01
Cash Cash Equivalents And Short Term Investments
—
2.61
-0.55%
2.62
-45.18%
4.78
Cash And Cash Equivalents
—
2.61
-0.55%
2.62
-45.18%
4.78
Cash Financial
—
2.61
-0.55%
2.62
-45.18%
4.78
Receivables
—
0.21
+36.83%
0.15
-7.73%
0.16
Receivables Adjustments Allowances
—
0.00
0.00
0.00
Other Receivables
—
0.04
+1224.36%
0.00
-85.83%
0.02
Taxes Receivable
—
0.16
+9.90%
0.15
+5.45%
0.14
Prepaid Assets
—
0.24
+1629.49%
0.01
-76.81%
0.06
Total Non Current Assets
—
1.41
-22.32%
1.81
+6.22%
1.71
Net PPE
—
0.65
-31.74%
0.95
-22.18%
1.23
Gross PPE
—
1.88
-3.52%
1.95
-3.99%
2.03
Accumulated Depreciation
—
-1.23
-23.49%
-1.00
-23.68%
-0.81
Properties
—
0.00
0.00
0.00
Machinery Furniture Equipment
—
0.07
+0.80%
0.07
+2.69%
0.06
Other Properties
—
1.61
-4.09%
1.68
-4.15%
1.75
Leases
—
0.20
-0.24%
0.20
-4.75%
0.21
Goodwill And Other Intangible Assets
—
0.12
-52.46%
0.25
-39.06%
0.41
Other Intangible Assets
—
0.12
-52.46%
0.25
-39.06%
0.41
Non Current Deferred Assets
—
0.64
+15.43%
0.55
0.00
Other Non Current Assets
—
-0.00
-100.00%
0.06
-20.97%
0.07
Total Liabilities Net Minority Interest
—
2.80
-15.10%
3.29
+2.25%
3.22
Current Liabilities
—
2.73
-16.58%
3.28
+9.56%
2.99
Payables And Accrued Expenses
—
2.67
-12.71%
3.06
+11.11%
2.75
Payables
—
2.67
-12.71%
3.06
+11.11%
2.75
Accounts Payable
—
0.62
-1.95%
0.63
-16.97%
0.76
Other Payable
—
1.26
+63.92%
0.77
-61.34%
1.99
Current Debt And Capital Lease Obligation
—
0.06
-71.27%
0.22
-8.50%
0.24
Current Capital Lease Obligation
—
0.06
-71.27%
0.22
-8.50%
0.24
Total Non Current Liabilities Net Minority Interest
—
0.06
+243.13%
0.02
-91.90%
0.23
Long Term Debt And Capital Lease Obligation
—
0.06
+243.13%
0.02
-91.90%
0.23
Long Term Capital Lease Obligation
—
0.06
+243.13%
0.02
-91.90%
0.23
Stockholders Equity
—
1.66
+27.40%
1.31
-62.61%
3.49
Common Stock Equity
—
1.66
+27.40%
1.31
-62.61%
3.49
Capital Stock
—
0.02
+0.00%
0.02
-79.80%
0.10
Common Stock
—
0.02
+0.00%
0.02
-79.80%
0.10
Share Issued
1.08
+0.00%
1.08
+0.00%
1.08
+0.00%
1.08
Ordinary Shares Number
1.08
+0.00%
1.08
+0.00%
1.08
+0.00%
1.08
Additional Paid In Capital
—
16.49
+20.63%
13.67
+8.67%
12.58
Retained Earnings
—
-15.97
-21.09%
-13.19
-39.46%
-9.46
Gains Losses Not Affecting Retained Earnings
—
1.12
+39.72%
0.80
+199.05%
0.27
Other Equity Adjustments
—
1.12
+39.72%
0.80
+199.05%
0.27
Total Equity Gross Minority Interest
—
1.66
+27.40%
1.31
-62.61%
3.49
Total Capitalization
—
1.66
+27.40%
1.31
-62.61%
3.49
Working Capital
—
0.32
+165.08%
-0.49
-124.29%
2.02
Invested Capital
—
1.66
+27.40%
1.31
-62.61%
3.49
Total Debt
—
0.13
-46.15%
0.24
-49.80%
0.47
Capital Lease Obligations
—
0.13
-46.15%
0.24
-49.80%
0.47
Net Tangible Assets
—
1.54
+46.34%
1.06
-65.75%
3.08
Tangible Book Value
—
1.54
+46.34%
1.06
-65.75%
3.08
Dueto Related Parties Current
—
0.79
-52.42%
1.66
0.00
Line Item Trend 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Operating Cash Flow
-2.13
+28.25%
-2.96
-299.71%
-0.74
-56.43%
-0.47
Cash Flow From Continuing Operating Activities
-2.13
+28.25%
-2.96
-299.71%
-0.74
-56.43%
-0.47
Net Income From Continuing Operations
-2.78
+25.46%
-3.73
+7.32%
-4.03
-119.24%
-1.84
Depreciation Amortization Depletion
0.40
+9.41%
0.37
+188.42%
0.13
+118.90%
0.06
Depreciation
0.27
+17.25%
0.23
+99.14%
0.11
+98.61%
0.06
Amortization Cash Flow
0.13
-3.74%
0.14
+1062.34%
0.01
0.00
Depreciation And Amortization
0.40
+9.41%
0.37
+188.42%
0.13
+118.90%
0.06
Amortization Of Intangibles
0.13
-3.74%
0.14
+1062.34%
0.01
0.00
Other Non Cash Items
-0.05
-149.95%
-0.02
-8707.41%
-0.00
-767.86%
-0.00
Asset Impairment Charge
—
0.00
-100.00%
1.62
0.00
Operating Gains Losses
—
0.15
+299.13%
0.04
—
Gain Loss On Sale Of PPE
—
0.00
-100.00%
0.04
0.00
Change In Working Capital
0.26
+1.03%
0.25
-83.13%
1.50
+15.22%
1.31
Change In Receivables
0.05
+149.95%
0.02
+8707.41%
0.00
+767.86%
0.00
Change In Prepaid Assets
-0.28
-139.93%
-0.12
-120.59%
0.57
-56.09%
1.29
Change In Payables And Accrued Expense
0.48
+25.80%
0.38
-58.22%
0.91
+5193.10%
0.02
Change In Payable
0.48
+25.80%
0.38
-58.22%
0.91
+5193.10%
0.02
Change In Account Payable
0.48
+25.80%
0.38
-58.22%
0.91
+5193.10%
0.02
Change In Other Current Assets
0.06
+276.84%
0.01
0.00
—
Change In Other Current Liabilities
0.00
+100.00%
-0.03
-200.00%
0.03
0.00
Investing Cash Flow
-0.07
+71.82%
-0.26
+75.73%
-1.08
-4159.43%
-0.03
Cash Flow From Continuing Investing Activities
-0.07
+71.82%
-0.26
+75.73%
-1.08
-4159.43%
-0.03
Net PPE Purchase And Sale
-0.07
+64.86%
-0.21
+75.50%
-0.86
-3282.89%
-0.03
Purchase Of PPE
-0.07
+64.86%
-0.21
+76.29%
-0.89
-3396.56%
-0.03
Sale Of PPE
—
0.00
-100.00%
0.03
0.00
Capital Expenditure
-0.07
+65.13%
-0.21
+83.80%
-1.31
-5057.34%
-0.03
Net Business Purchase And Sale
0.00
+100.00%
-0.05
-125.30%
0.20
0.00
Purchase Of Business
—
-0.05
0.00
—
Gain Loss On Sale Of Business
0.00
-100.00%
0.15
0.00
—
Net Intangibles Purchase And Sale
0.00
+100.00%
-0.00
+99.61%
-0.42
0.00
Purchase Of Intangibles
0.00
+100.00%
-0.00
+99.61%
-0.42
0.00
Financing Cash Flow
1.87
+307.48%
0.46
-92.49%
6.10
+774.56%
0.70
Cash Flow From Continuing Financing Activities
1.87
+307.48%
0.46
-92.49%
6.10
+774.56%
0.70
Net Issuance Payments Of Debt
1.66
0.00
—
—
Issuance Of Debt
1.66
0.00
—
—
Long Term Debt Issuance
1.66
0.00
—
—
Net Long Term Debt Issuance
1.66
0.00
—
—
Net Common Stock Issuance
-0.09
-108.44%
1.01
-83.41%
6.10
+774.56%
0.70
Net Other Financing Charges
0.29
+153.28%
-0.55
—
—
Changes In Cash
-0.33
+87.95%
-2.77
-164.81%
4.27
+2060.33%
0.20
Effect Of Exchange Rate Changes
0.32
-47.39%
0.61
+36.10%
0.45
+325.76%
-0.20
Beginning Cash Position
2.62
-45.18%
4.78
+7156.86%
0.07
+0.33%
0.07
End Cash Position
2.61
-0.55%
2.62
-45.18%
4.78
+7156.86%
0.07
Free Cash Flow
-2.20
+30.72%
-3.18
-54.66%
-2.05
-311.20%
-0.50
Interest Paid Supplemental Data
0.00
0.00
0.00
0.00
Income Tax Paid Supplemental Data
0.00
0.00
0.00
0.00
Common Stock Issuance
0.00
-100.00%
1.01
-83.41%
6.10
+774.56%
0.70
Interest Received CFO
0.05
+149.95%
0.02
+8707.41%
0.00
+767.86%
0.00
Issuance Of Capital Stock
0.00
-100.00%
1.01
-83.41%
6.10
+774.56%
0.70
Sale Of Business
0.00
—
0.20
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category